Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38823398

Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Gastroenterol Hepatol
Publication date
2024 Aug
First author
Oh DY

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Gastroenterol Hepatol. 2024 Aug;9(8):678-679. doi: 10.1016/S2468-1253(24)00118-3.
    note
    Source null
    related pmid
    38823400
    relationship
    Comment in
  2. citation
    Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316.
    note
    Source null
    related pmid
    40893741
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2025 Oct 1;14(5):839-842. doi: 10.21037/hbsn-2025-393.
    note
    Source null
    related pmid
    41104197
    relationship
    Comment in
  4. citation
    Hepatobiliary Surg Nutr. 2025 Dec 1;14(6):1009-1011. doi: 10.21037/hbsn-2025-367.
    note
    Source null
    related pmid
    41383674
    relationship
    Comment in

Authors and identifiers

  1. name
    Oh DY
    type
    Author
  2. name
    He AR
    type
    Author
  3. name
    Bouattour M
    type
    Author
  4. name
    Okusaka T
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Chen LT
    type
    Author
  7. name
    Kitano M
    type
    Author
  8. name
    Lee CK
    type
    Author
  9. name
    Kim JW
    type
    Author
  10. name
    Chen MH
    type
    Author
  11. name
    Suksombooncharoen T
    type
    Author
  12. name
    Ikeda M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Oh DY
    type
    Author
  2. name
    He AR
    type
    Author
  3. name
    Bouattour M
    type
    Author
  4. name
    Okusaka T
    type
    Author
  5. name
    Qin S
    type
    Author
  6. name
    Chen LT
    type
    Author
  7. name
    Kitano M
    type
    Author
  8. name
    Lee CK
    type
    Author
  9. name
    Kim JW
    type
    Author
  10. name
    Chen MH
    type
    Author
  11. name
    Suksombooncharoen T
    type
    Author
  12. name
    Ikeda M
    type
    Author
bibliography ids
  1. nci-bib-a1d1787761770207887c4a26
book metadata
content sha256
a080a390d0c337c360a01fc9958c1903d0eb7899012939daf62270c0f4cc509d
document type
citation
dois
  1. 10.1016/S2468-1253(24)00095-5
electronic publication date
display
2024 May 29
precision
day
year
2024
evidence scope
bibliographic_metadata_only
id
pubmed:38823398
immutable id
pubmed:38823398@a080a390d0c337c360a01fc9958c1903d0eb7899012939daf62270c0f4cc509d
journal
abbreviation
Lancet Gastroenterol Hepatol
issn electronic
2468-1253
issn print
Source null
issue
8
name
The lancet. Gastroenterology & hepatology
nlm unique id
101690683
pages
694-704
volume
9
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Gastroenterol Hepatol. 2024 Aug;9(8):678-679. doi: 10.1016/S2468-1253(24)00118-3.
    note
    Source null
    related pmid
    38823400
    relationship
    Comment in
  2. citation
    Hepatobiliary Surg Nutr. 2025 Aug 1;14(4):676-679. doi: 10.21037/hbsn-2025-316.
    note
    Source null
    related pmid
    40893741
    relationship
    Comment in
  3. citation
    Hepatobiliary Surg Nutr. 2025 Oct 1;14(5):839-842. doi: 10.21037/hbsn-2025-393.
    note
    Source null
    related pmid
    41104197
    relationship
    Comment in
  4. citation
    Hepatobiliary Surg Nutr. 2025 Dec 1;14(6):1009-1011. doi: 10.21037/hbsn-2025-367.
    note
    Source null
    related pmid
    41383674
    relationship
    Comment in
outcomes validated
false
pmid
38823398
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
9e117fb48cb69880fc1a059df13995c8e5155496be8764112c255fa8633ab947
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Aug
precision
month
year
2024
publication types
  1. Journal Article
  2. Randomized Controlled Trial
  3. Clinical Trial, Phase III
  4. Multicenter Study
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38823398/
title
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.

Preserved source evidence · Not medical advice